Literature DB >> 17027909

Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme.

Cynthia E Hernandez1, Santosh Kumar, Hong Liu, James R Halpert.   

Abstract

Based on the X-ray crystal structures of 4-(4-chlorophenyl)imidazole (4-CPI)- and bifonazole (BIF)-bound P450 2B4, eight active site mutants at six positions were created in an N-terminal modified construct termed 2B4dH and characterized for enzyme inhibition and catalysis. I363A showed a >4-fold decrease in differential inhibition by BIF and 4-CPI (IC(50,BIF)/IC(50,4-CPI)). F296A, T302A, I363A, V367A, and V477A showed a 2-fold decreased k(cat) for 7-ethoxy-4-trifluoromethylcoumarin O-deethylation, whereas V367A and V477F showed an altered K(m). T302A, V367L, and V477A showed >4-fold decrease in total testosterone hydroxylation, whereas I363A, V367A, and V477F showed altered stereo- and regioselectivity. Interestingly, I363A showed a 150-fold enhanced k(cat)/K(m) with testosterone, and yielded a new metabolite. Furthermore, testosterone docking into three-dimensional models of selected mutants based on the 4-CPI-bound structure suggested a re-positioning of residues 363 and 477 to yield products. In conclusion, our results suggest that the 4-CPI-bound 2B4dH/H226Y crystal structure is an appropriate model for predicting enzyme catalysis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027909      PMCID: PMC1773018          DOI: 10.1016/j.abb.2006.08.024

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  28 in total

1.  Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis.

Authors:  L Afzelius; I Zamora; M Ridderström; T B Andersson; A Karlén; C M Masimirembwa
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

2.  A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function.

Authors:  E E Scott; M Spatzenegger; J R Halpert
Journal:  Arch Biochem Biophys       Date:  2001-11-01       Impact factor: 4.013

Review 3.  Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis.

Authors:  T L Domanski; J R Halpert
Journal:  Curr Drug Metab       Date:  2001-06       Impact factor: 3.731

4.  A rational approach to Re-engineer cytochrome P450 2B1 regioselectivity based on the crystal structure of cytochrome P450 2C5.

Authors:  Santosh Kumar; Emily E Scott; Hong Liu; James R Halpert
Journal:  J Biol Chem       Date:  2003-02-27       Impact factor: 5.157

5.  Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling.

Authors:  Margit Spatzenegger; Hong Liu; Qinmi Wang; Andrea Debarber; Dennis R Koop; James R Halpert
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

6.  Conformational flexibility of mammalian cytochrome P450 2B4 in binding imidazole inhibitors with different ring chemistry and side chains. Solution thermodynamics and molecular modeling.

Authors:  B K Muralidhara; Surendra Negi; Christopher C Chin; Werner Braun; James R Halpert
Journal:  J Biol Chem       Date:  2006-01-26       Impact factor: 5.157

7.  Substrate routes to the buried active site may vary among cytochromes P450: mutagenesis of the F-G region in P450 2B1.

Authors:  Emily E Scott; You Qun He; James R Halpert
Journal:  Chem Res Toxicol       Date:  2002-11       Impact factor: 3.739

8.  Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template.

Authors:  David F V Lewis
Journal:  J Inorg Biochem       Date:  2002-09-20       Impact factor: 4.155

9.  An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution.

Authors:  Emily E Scott; You Ai He; Michael R Wester; Mark A White; Christopher C Chin; James R Halpert; Eric F Johnson; C David Stout
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

10.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.

Authors:  P A Williams; J Cosme; V Sridhar; E F Johnson; D E McRee
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

View more
  14 in total

1.  Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity.

Authors:  Sean C Gay; Haoming Zhang; P Ross Wilderman; Arthur G Roberts; Tong Liu; Sheng Li; Hsia-Lien Lin; Qinghai Zhang; Virgil L Woods; C David Stout; Paul F Hollenberg; James R Halpert
Journal:  Biochemistry       Date:  2011-05-13       Impact factor: 3.162

2.  Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide.

Authors:  Ling Sun; Chong S Chen; David J Waxman; Hong Liu; James R Halpert; Santosh Kumar
Journal:  Arch Biochem Biophys       Date:  2007-01-08       Impact factor: 4.013

3.  NMR-derived models of amidopyrine and its metabolites in complexes with rabbit cytochrome P450 2B4 reveal a structural mechanism of sequential N-dealkylation.

Authors:  Arthur G Roberts; Sara E A Sjögren; Nadezda Fomina; Kathy T Vu; Adah Almutairi; James R Halpert
Journal:  Biochemistry       Date:  2011-03-04       Impact factor: 3.162

4.  Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzyme.

Authors:  P Ross Wilderman; Sean C Gay; Hyun-Hee Jang; Qinghai Zhang; C David Stout; James R Halpert
Journal:  FEBS J       Date:  2011-11-25       Impact factor: 5.542

5.  X-ray crystal structure of the cytochrome P450 2B4 active site mutant F297A in complex with clopidogrel: insights into compensatory rearrangements of the binding pocket.

Authors:  Manish B Shah; Hyun-Hee Jang; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2013-01-04       Impact factor: 4.013

6.  Roles of Residues F206 and V367 in Human CYP2B6: Effects of Mutations on Androgen Hydroxylation, Mechanism-Based Inactivation, and Reversible Inhibition.

Authors:  Hsia-Lien Lin; Haoming Zhang; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2016-08-18       Impact factor: 3.922

7.  Rational engineering of cytochromes P450 2B6 and 2B11 for enhanced stability: Insights into structural importance of residue 334.

Authors:  Jyothi C Talakad; P Ross Wilderman; Dmitri R Davydov; Santosh Kumar; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2009-11-26       Impact factor: 4.013

8.  Structural and thermodynamic consequences of 1-(4-chlorophenyl)imidazole binding to cytochrome P450 2B4.

Authors:  Yonghong Zhao; Ling Sun; B K Muralidhara; Santosh Kumar; Mark A White; C David Stout; James R Halpert
Journal:  Biochemistry       Date:  2007-09-22       Impact factor: 3.162

9.  Identification and analysis of conserved sequence motifs in cytochrome P450 family 2. Functional and structural role of a motif 187RFDYKD192 in CYP2B enzymes.

Authors:  Numan Oezguen; Santosh Kumar; Aditya Hindupur; Werner Braun; B K Muralidhara; James R Halpert
Journal:  J Biol Chem       Date:  2008-05-21       Impact factor: 5.157

Review 10.  Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation.

Authors:  Santosh Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-02       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.